

# Tara L Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2510782/publications.pdf>

Version: 2024-02-01

113  
papers

3,906  
citations

279487

23  
h-index

133063

59  
g-index

114  
all docs

114  
docs citations

114  
times ranked

6058  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018, 562, 526-531.	13.7	907
2	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2684-2692.	0.8	682
3	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1277-1284.	0.8	494
4	Role of the Aggresome Pathway in Cancer: Targeting Histone Deacetylase 6-Dependent Protein Degradation. <i>Cancer Research</i> , 2008, 68, 2557-2560.	0.4	155
5	Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. <i>Journal of Clinical Oncology</i> , 2016, 34, 7000-7000.	0.8	130
6	Hedgehog pathway as a drug target: Smoothed inhibitors in development. <i>OncoTargets and Therapy</i> , 2012, 5, 47.	1.0	126
7	Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. <i>Nature Medicine</i> , 2020, 26, 1852-1858.	15.2	104
8	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e481-e491.	2.2	92
9	A novel three-dimensional stromal-based model for <i>in vitro</i> chemotherapy sensitivity testing of leukemia cells. <i>Leukemia and Lymphoma</i> , 2014, 55, 378-391.	0.6	89
10	Overcoming Wnt- $\beta$ -catenin dependent anticancer therapy resistance in leukaemia stem cells. <i>Nature Cell Biology</i> , 2020, 22, 689-700.	4.6	89
11	Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926. <i>PLoS ONE</i> , 2010, 5, e15262.	1.1	75
12	Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2016, 51, 1268-1270.	1.3	68
13	The aggresome pathway as a target for therapy in hematologic malignancies. <i>Molecular Genetics and Metabolism</i> , 2008, 94, 283-286.	0.5	63
14	A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumorigenic potential. <i>British Journal of Haematology</i> , 2012, 158, 79-90.	1.2	50
15	A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6132-6140.	3.2	45
16	Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. <i>Leukemia and Lymphoma</i> , 2011, 52, 1544-1555.	0.6	43
17	Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 564-564.	0.6	41
18	Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes. <i>Blood</i> , 2017, 130, 890-890.	0.6	41

#	ARTICLE	IF	CITATIONS
19	Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation. <i>Blood</i> , 2016, 128, 3000-3010.	0.6	32
20	Acute Myeloid Leukemia: Focus on novel Therapeutic Strategies. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7244.	0.6	31
21	Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of <i>HOXA9</i> and <i>MEIS1</i> Expression. <i>Clinical Cancer Research</i> , 2020, 26, 5852-5859.	3.2	28
22	Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 15-15.	0.6	27
23	PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis. <i>Blood</i> , 2018, 132, 466-466.	0.6	24
24	Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2016, 31, 347-352.	0.7	22
25	Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age $\geq$ 65 with acute myelogenous leukemia.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7007-7007.	0.8	22
26	A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 74.	1.7	21
27	A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Cancers</i> , 2021, 13, 4113.	1.7	20
28	Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation. <i>Annals of Hematology</i> , 2014, 93, 847-854.	0.8	19
29	Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34+ cells in a murine model of umbilical cord blood transplantation. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 52, 59-67.	0.6	19
30	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. <i>British Journal of Haematology</i> , 2019, 185, 595-598.	1.2	19
31	A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results. <i>Blood</i> , 2020, 136, 16-17.	0.6	19
32	Tubacin, An Inhibitor of HDAC6, Induces Apoptosis of Acute Lymphoblastic Leukemia Cells in Vitro and in Vivo through a Na <sup>+</sup> /K <sup>+</sup> ATPase-Dependent Pathway.. <i>Blood</i> , 2008, 112, 1923-1923.	0.6	18
33	Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7510-7510.	0.8	16
34	A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics. <i>Leukemia Research</i> , 2018, 72, 105-112.	0.4	15
35	Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1641-1645.	2.0	14
36	Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. <i>Leukemia Research</i> , 2020, 95, 106402.	0.4	13

#	ARTICLE	IF	CITATIONS
37	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. <i>Blood Advances</i> , 2021, 5, 1719-1728.	2.5	13
38	Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of <i>Clostridium difficile</i> infections in allogeneic stem cell transplant. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 233-240.	0.6	12
39	First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. <i>Blood</i> , 2020, 136, 36-36.	0.6	12
40	Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 228-234.	0.5	11
41	A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 163-173.	1.1	10
42	Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1965-1973.	0.6	10
43	Prognostically Important Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia. <i>American Journal of the Medical Sciences</i> , 2011, 341, 404-408.	0.4	9
44	IgG kappa monoclonal gammopathy of undetermined significance presenting as acquired type III Von Willebrand syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 631-633.	0.5	8
45	Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2020, 136, 11-12.	0.6	8
46	Rates of complete diagnostic testing for patients with acute myeloid leukemia. <i>Cancer Medicine</i> , 2015, 4, 519-522.	1.3	7
47	Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1713-1719.	2.0	7
48	Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 171-173.	0.6	7
49	Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment. <i>Annals of Hematology</i> , 2019, 98, 481-489.	0.8	7
50	Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1188-1194.	0.6	7
51	High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 99-109.	0.7	7
52	CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2510-2510.	0.6	7
53	Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 691-697.	1.1	6
54	A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant. <i>Journal of Clinical Apheresis</i> , 2016, 31, 559-563.	0.7	6

#	ARTICLE	IF	CITATIONS
55	Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 110.	6.9	6
56	Outpatient Cytarabine Administration Is Safe and Effective For Consolidation In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 5030-5030.	0.6	6
57	Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies. <i>Leukemia and Lymphoma</i> , 2022, 63, 1708-1713.	0.6	6
58	Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells. <i>Molecular Cancer Research</i> , 2021, 19, 913-920.	1.5	5
59	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML. <i>Blood</i> , 2020, 136, 44-45.	0.6	5
60	Cancer Stem Cells: The Root of the Problem. <i>Pediatric Research</i> , 2007, 62, 239-239.	1.1	4
61	The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 303-314.	1.0	4
62	Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission. <i>Blood</i> , 2019, 134, 1316-1316.	0.6	3
63	A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3165-TPS3165.	0.8	3
64	A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 175.	2.8	3
65	Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 3979-3979.	0.6	2
66	Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 55-56.	0.6	2
67	Resistance To Chemotherapy In Leukemia Cells Grown On An Extracellular Matrix-Based Leukemia Model Derived From Wharton's Jelly. <i>Blood</i> , 2013, 122, 1388-1388.	0.6	2
68	Efficacy and Relative Costs Of Re-Induction Chemotherapy With Clofarabine and Cytarabine For Adults With AML. <i>Blood</i> , 2013, 122, 5043-5043.	0.6	2
69	Blinatumomab for Relapsed/Refractory Acute Lymphocytic Leukemia: A Single Center Experience. <i>Blood</i> , 2015, 126, 4912-4912.	0.6	2
70	A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS7561-TPS7561.	0.8	2
71	Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS7567-TPS7567.	0.8	2
72	Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial. <i>Blood</i> , 2021, 138, 1268-1268.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Functional characterization of NPM1-TYK2 fusion oncogene. <i>Npj Precision Oncology</i> , 2022, 6, 3.	2.3	2
74	A phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated acute myeloid leukemia ≥ age 60 years: Phase 1b interim results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7027-7027.	0.8	2
75	Umbilical cord graft-versus-leukemia effect induces remission without the price of graft-versus-host disease: the possible role of <sc>NK</sc> cells. <i>Clinical Transplantation</i> , 2012, 26, 663-664.	0.8	1
76	Skin Recurrence of Transformed Mycosis Fungoides Postumbilical Cord Blood Transplant despite Complete Donor Chimerism. <i>Case Reports in Hematology</i> , 2014, 2014, 1-5.	0.3	1
77	High-Risk Microgranular Acute Promyelocytic Leukemia with a Five-Way Complex Translocation Involving PML-RARA. <i>Case Reports in Hematology</i> , 2015, 2015, 1-3.	0.3	1
78	Evaluation of cytomegalovirus reactivation and tolerability in seropositive umbilical cord transplant patients after implementation of an intensive prevention strategy. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 105-111.	0.6	1
79	Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 135-141.	0.6	1
80	The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML. <i>Blood</i> , 2018, 132, 2706-2706.	0.6	1
81	Impact of Erythropoietin Modulation Using Hyperbaric Oxygen on Umbilical Cord Blood CD34+ Cell Homing. <i>Blood</i> , 2015, 126, 1870-1870.	0.6	1
82	N-Cadherin Immunoexpression in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4944-4944.	0.6	1
83	A Novel 3D Extracellular Matrix Model Enriching Human Acute Myeloid Leukemia Stem Cells. <i>Blood</i> , 2015, 126, 4959-4959.	0.6	1
84	Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7042-7042.	0.8	1
85	Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA. <i>Frontiers in Oncology</i> , 2021, 11, 806243.	1.3	1
86	Acute promyelocytic leukemia: A single institution's experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19001-e19001.	0.8	1
87	V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7043-7043.	0.8	1
88	Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7031-7031.	0.8	1
89	Adjuvant therapy for resected non-small-cell lung cancer: Recent advances, emerging agents, and lingering questions. <i>Current Oncology Reports</i> , 2004, 6, 251-258.	1.8	0
90	Research Highlights: Highlights from the latest articles in molecular profiling and prognosis in acute myeloid leukemia. <i>Personalized Medicine</i> , 2012, 9, 679-682.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution. <i>Acta Haematologica</i> , 2018, 139, 52-57.	0.7	0
92	Abstract P13: Prospective voluntary SARS-CoV-2 virus and anti-COVID-19 antibody tests in asymptomatic medical and research staff who work in direct contact with cancer patients: A single center study. , 2021, , .		0
93	Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7026-7026.	0.8	0
94	Propylene Glycol-Free Melphalan Induces Higher Remission Rates in Multiple Myeloma Patients Undergoing Autologous Transplantation. <i>Blood</i> , 2012, 120, 4551-4551.	0.6	0
95	Hyperbaric Oxygen Therapy Improves Post-Transplant Umbilical Cord Blood Engraftment. <i>Blood</i> , 2012, 120, 4663-4663.	0.6	0
96	N-Cadherin Immunoexpression In Patients With Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 4976-4976.	0.6	0
97	Pilot Clinical Study Incorporating Hyperbaric Oxygen into Umbilical Cord Blood Transplantation. <i>Blood</i> , 2014, 124, 3889-3889.	0.6	0
98	Correlation Between Markers of Bone Turnover and Vitamin D Levels in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS). <i>Blood</i> , 2014, 124, 3471-3471.	0.6	0
99	Final Results of the First-in-Human Clinical Study Incorporating Hyperbaric Oxygen into Umbilical Cord Blood Transplantation. <i>Blood</i> , 2015, 126, 1909-1909.	0.6	0
100	Impact of Hyperbaric Oxygen Treatment on Time to Transfusion Independency Post-UCB Transplant. <i>Blood</i> , 2015, 126, 4333-4333.	0.6	0
101	A pilot study using hyperbaric oxygen therapy to improve umbilical cord blood stem cell engraftment: 6-months follow up results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7048-7048.	0.8	0
102	Transfusion support and post-transplant complications in autologous transplant patients receiving hyperbaric oxygen.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19004-e19004.	0.8	0
103	Effect of hyperbaric oxygen treatment on chemotherapy sensitivity in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18518-e18518.	0.8	0
104	Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7040-7040.	0.8	0
105	Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML). <i>Blood</i> , 2018, 132, 1434-1434.	0.6	0
106	The prognosis of NF1 mutations in newly diagnosed AML: A single-center retrospective study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18525-e18525.	0.8	0
107	Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells. <i>Blood</i> , 2019, 134, 2865-2865.	0.6	0
108	Outcomes in older patients with high-risk/secondary AML who achieved remission with CPX-351 versus 7+3 but did not undergo transplant: Phase 3 exploratory analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7537-7537.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Use of Endpoints in Phase III Randomized Controlled Trials for Acute Myeloid Leukemia over the Last 15 Years: A Systematic Review. <i>Blood</i> , 2021, 138, 4389-4389.	0.6	0
110	Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results. <i>Blood</i> , 2021, 138, 2316-2316.	0.6	0
111	V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-28.	0.6	0
112	Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7069-TPS7069.	0.8	0
113	Bringing experimental therapeutics clinical trials network (ETCTN) to underrepresented population.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6542-6542.	0.8	0